In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum.
More info..

CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, 'CanSinoBIO' or the 'Company'), a leading player in China's vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&D innovation and strong commercial capabilities.
More info..

CanSino Biologics Inc. ("CanSinoBIO" or "the Company") has announced a milestone in its fight against polio.
More info..

CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced.
More info..

On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the Chinese Center for Disease Control and Prevention (China CDC) took place in the Xiong'an New Area of Hebei Province.
More info..

In 2023, CanSinoBIO's meningococcal conjugate vaccine achieved revenue approximately RMB561.72 million, representing a year-on-year increase of approximately 266.39% compared to last year. The growth trend is evident.
More info..